Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders

• US 7,923,449 B2
• Filed: 10/25/2006
• Issued: 04/12/2011
• Est. Priority Date: 10/29/2005
• Status: Expired due to Fees

• Current Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Ceci, Angelo
• Primary Examiner(s): Hui; San-ming
• Application Number:
  US12/091,848
• Publication Number:
  US 20080242679A1
• Time in Patent Office: 1,630 Days
• Field of Search: 514/254.06
• US Class Current: 514/254.06
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/02 for disorders of the vagina
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 15/12 for climacteric disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to the use of benzimidazolone derivatives of formula (I) for the preparation of a medicament for the treatment of premenstrual and other female sexual disorders.

Claims

1. A method of treating a premenstrual disorder comprising administering to an individual a therapeutically effective amount of a compound of formula (I)

2. The method according to claim 1, wherein the premenstrual disorder comprises premenstrual dysphoria, premenstrual syndrome, or premenstrual dysphoric disorder.

3. The method according to claim 1, wherein the compound of formula (I) is administered as a pharmaceutically acceptable acid addition salt formed by an acid comprising maleic, citric, tartaric, methanesulphonic, acetic, benzoic, succinic, gluconic, isethionic, glycinic, lactic, malic, mucoic, glutamic, sulphamic, ascorbic, hydrochloric, hydrobromic, nitric, sulfuric, phosphoric, or mixtures thereof.

4. The method according to claim 1, wherein the compound of formula (I) is administered in a dosage range between 0.1 and 400 mg per day.

5. The method according to claim 1, wherein the compound of formula (I) is compound (I.a)

6. The method according to claim 1, wherein the compound of formula (I) is compound (I.b)

7. The method according to claim 1, wherein the compound of formula (I) is compound (I.c)

8. The method according to claim 1, wherein the compound of formula (I) is compound (I.d)

9. The method according to claim 1, wherein the compound of formula (I) is compound (I.c)

10. The method according to claim 1, wherein the compound of formula (I) is compound (I.f)

11. The method according to claim 1, wherein the compound of formula (I) is compound (I.g)

12. The method according to claim 1, wherein the compound of formula (I) is compound (I.h)